A Phase 2, Single Arm Study Evaluating the Safety and Efficacy of Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Phase of Trial: Phase II
Latest Information Update: 23 May 2017
Price : $35 *
At a glance
- Drugs Idelalisib (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 17 May 2016 Status changed from active, no longer recruiting to discontinued.
- 16 Mar 2016 Planned End Date changed from 1 Oct 2018 to 1 May 2016, according to ClinicalTrials.gov record.
- 16 Mar 2016 Planned primary completion date changed from 1 Oct 2018 to 1 May 2016, according to ClinicalTrials.gov record.